REGCON HOLDINGS
GenericsREGCON HOLDINGS is a generic drug manufacturer focused on Cardiovascular, Neurology, Oncology.
REGCON HOLDINGS's Key Drugs
REGCON HOLDINGS's core commercial portfolio centers on BRIMONIDINE TARTRATE AND TIMOLOL MALEATE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
REGCON HOLDINGS's Recent FDA Approvals
REGCON HOLDINGS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
REGCON HOLDINGS's Therapeutic Areas
REGCON HOLDINGS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
REGCON HOLDINGS's Top Competitors
REGCON HOLDINGS's closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and Bayer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
REGCON HOLDINGS Pipeline Snapshot
Active clinical trials for REGCON HOLDINGS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • BRIMONIDINE TARTRATE AND TIMOLOL MALEATE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1999-01-26
- Latest
- 2026-06-22
- Applications
- 47